Evidence-Based Guideline for the Treatment of Smoking Cessation Provided by the National Health Insurance Service in Korea
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Although major countries, such as South Korea, have developed and disseminated national smoking cessation guide-lines, these efforts have been limited to developing individual societies or specialized institution-based recommenda-tions. Therefore, evidence-based clinical guidelines are essential for developing smoking cessation interventions and promoting effective smoking cessation treatments. This guideline targets frontline clinical practitioners involved in a smoking cessation treatment support program implemented in 2015 with the support of the National Health Insurance Service. The Guideline Development Group of 10 multidisciplinary smoking cessation experts employed the Grading of Recommendations Assessment, Development, and Evaluation (GRADE)-ADOLOPMENT approach to review recent do-mestic and international research and guidelines and to determine evidence levels using the GRADE methodology. The guideline panel formulated six strong recommendations and one conditional recommendation regarding pharmaco-therapy choices among general and special populations (mental disorders and chronic obstructive lung disease [COPD]). Strong recommendations favor varenicline rather than a nicotine patch or bupropion, using varenicline even if they are not ready to quit, using extended pharmacotherapy (>12 weeks) rather than standard treatment (8–12 weeks), or using pharmacotherapy for individuals with mental disorders or COPD. The conditional recommendation suggests combining varenicline with a nicotine patch instead of using varenicline alone. Aligned with the Korean Society of Medicine’s clinical guideline development process, this is South Korea’s first domestic smoking cessation treatment guideline that follows standardized guidelines. Primarily focusing on pharmacotherapy, it can serve as a foundation for comprehensive future smoking cessation clinical guidelines, encompassing broader treatment topics beyond medications.
Abstract
Although major countries, such as South Korea, have developed and disseminated national smoking cessation guide-lines, these efforts have been limited to developing individual societies or specialized institution-based recommenda-tions. Therefore, evidence-based clinical guidelines are essential for developing smoking cessation interventions and promoting effective smoking cessation treatments. This guideline targets frontline clinical practitioners involved in a smoking cessation treatment support program implemented in 2015 with the support of the National Health Insurance Service. The Guideline Development Group of 10 multidisciplinary smoking cessation experts employed the Grading of Recommendations Assessment, Development, and Evaluation (GRADE)-ADOLOPMENT approach to review recent do-mestic and international research and guidelines and to determine evidence levels using the GRADE methodology. The guideline panel formulated six strong recommendations and one conditional recommendation regarding pharmaco-therapy choices among general and special populations (mental disorders and chronic obstructive lung disease [COPD]). Strong recommendations favor varenicline rather than a nicotine patch or bupropion, using varenicline even if they are not ready to quit, using extended pharmacotherapy (>12 weeks) rather than standard treatment (8–12 weeks), or using pharmacotherapy for individuals with mental disorders or COPD. The conditional recommendation suggests combining varenicline with a nicotine patch instead of using varenicline alone. Aligned with the Korean Society of Medicine’s clinical guideline development process, this is South Korea’s first domestic smoking cessation treatment guideline that follows standardized guidelines. Primarily focusing on pharmacotherapy, it can serve as a foundation for comprehensive future smoking cessation clinical guidelines, encompassing broader treatment topics beyond medications.
참고문헌 (63)
- GBD 2019 Tobacco Collaborators, "Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990-2019 : a systematic analysis from the Global Burden of Disease Study 2019", Lancet, 397, pp.2337~2360 (2021)
- World Health Organization, "WHO Framework Convention on Tobacco Control: guidelines for implementation", World Health Organization, ~ (2011)
- Nilan K, "A survey of tobacco dependence treatment guidelines content in 61 countries", Addiction, 113, pp.1499~1506 (2018)
- Korea National Health and Nutrition Examination Survey (KNHANES) reports, "Korea Centers for Disease Control and Prevention", Korea Centers for Disease Control and Prevention, ~ (2020)
- Hwang JS, "Recent updates of pharmacotherapy for smoking cessation", Korean J Fam Pract, 11, pp.403~414 (2021)
- Schunemann HJ, "GRADE evidence to decision(EtD)frameworks for adoption, adaptation, and de novo development of trustworthy recommendations : GRADE-ADOLOPMENT", J Clin Epidemiol, 81, pp.101~110 (2017)
- Kim SY, "NECA’s handbook for clinical practice guideline developer, version 2.0" (2022), National Evidence-based Healthcare Collaborating Agency
- Brouwers MC, "AGREE II : advancing guideline development, reporting and evaluation in health care", CMAJ, 182, pp.E839~E842 (2010)
- Shea BJ, "Development of AMSTAR : a measurement tool to assess the methodological quality of systematic reviews", BMC Med Res Methodol, 7, pp.10~ (2007)
- Sterne JA, "RoB 2 : a revised tool for assessing risk of bias in randomized trials", BMJ, 366, pp.l4898~ (2019)
- Leone FT, "Initiating pharmacologic treatment in tobacco-dependent adults : an official American Thoracic Society Clinical Practice Guideline", Am J Respir Crit Care Med, 202, pp.e5~e31 (2020)
- Aubin HJ, "Varenicline versus transdermal nicotine patch for smoking cessation : results from a randomised open-label trial", Thorax, 63, pp.717~724 (2008)
- Anthenelli RM, "Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders(EAGLES) : a double-blind, randomised, placebo-controlled clinical trial", Lancet, 387, pp.2507~2520 (2016)
- de Dios MA, "Project Impact : a pharmacotherapy pilot trial investigating the abstinence and treatment adherence of Latino light smokers", J Subst Abuse Treat, 43, pp.322~330 (2012)
- Baker TB, "Effects of nicotine patch vs varenicline vs combination nicotine replacement therapy on smoking cessation at 26 weeks : a randomized clinical trial", JAMA, 315, pp.371~379 (2016)
- Heydari G, "Quitting smoking with varenicline : parallel, randomised efficacy trial in Iran", Int J Tuberc Lung Dis, 16, pp.268~272 (2012)
- Lerman C, "Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation : a randomised, double-blind placebo-controlled trial", Lancet Respir Med, 3, pp.131~138 (2015)
- Rohsenow DJ, "Varenicline versus nicotine patch with brief advice for smokers with substance use disorders with or without depression : effects on smoking, substance use and depressive symptoms", Addiction, 112, pp.1808~1820 (2017)
- Tsukahara H, "A randomized controlled open comparative trial of varenicline vs nicotine patch in adult smokers : efficacy, safety and withdrawal symptoms(the VN-SEESAW study)", Circ J, 74, pp.771~778 (2010)
- Tulloch HE, "Flexible, dual-form nicotine replacement therapy or varenicline in comparison with nicotine patch for smoking cessation : a randomized controlled trial", BMC Med, 14, pp.80~ (2016)
- Tuisku A, "Varenicline and nicotine patch therapies in young adults motivated to quit smoking : a randomized, placebo-controlled, prospective study", Basic Clin Pharmacol Toxicol, 119, pp.78~84 (2016)
- "Mechanistic Evaluations of Pre-Cessation Therapies for Smoking Cessation (ConNicBrain): NCT01406223" (2017)[URL]
- Lindson N, "Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation", Cochrane Database Syst Rev, 4, pp.CD013308~ (2019)
- Gomez-Coronado N, "Current and emerging pharmacotherapies for cessation of tobacco smoking", Pharmacotherapy, 38, pp.235~258 (2018)
- Jorenby DE, "Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation : a randomized controlled trial", JAMA, 296, pp.56~63 (2006)
- Gonzales D, "Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation : a randomized controlled trial", JAMA, 296, pp.47~55 (2006)
- Cinciripini PM, "Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal", JAMA Psychiatry, 70, pp.522~533 (2013)
- Gray KM, "Varenicline versus bupropion XL for smoking cessation in older adolescents : a randomized, double-blind pilot trial", Nicotine Tob Res, 14, pp.234~239 (2012)
- Nides M, "Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist : results from a 7-week, randomized, placebo-and bupropion-controlled trial with 1-year follow-up", Arch Intern Med, 166, pp.1561~1568 (2006)
- "The effect of varenicline (Chantix) and bupropion (Zyban)on smoking lapse behavior" (2018)[URL]
- Shang X, "Pharmacological interventions on smoking cessation : a systematic review and network meta-analysis", Front Pharmacol, 13, pp.1012433~ (2022)
- Ramon JM, "Combining varenicline and nicotine patches : a randomized controlled trial study in smoking cessation", BMC Med, 12, pp.172~ (2014)
- Koegelenberg CF, "Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation : a randomized clinical trial", JAMA, 312, pp.155~161 (2014)
- Baker TB, "Effects of combined varenicline with nicotine patch and of extended treatment duration on smoking cessation : a randomized clinical trial", JAMA, 326, pp.1485~1493 (2021)
- Schnoll R, "A randomized controlled trial of 24 weeks of varenicline for tobacco use among cancer patients : efficacy, safety, and adherence", Psychooncology, 28, pp.561~569 (2019)
- Murray RL, "Extended duration treatment of tobacco dependence : a systematic review and meta-analysis", Ann Am Thorac Soc, 19, pp.1390~1403 (2022)
- Croghan IT, "Randomized comparison of a nicotine inhaler and bupropion for smoking cessation and relapse prevention", Mayo Clin Proc, 82, pp.186~195 (2007)
- Evins AE, "Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder : a randomized clinical trial", JAMA, 311, pp.145~154 (2014)
- Hays JT, "Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. a randomized, controlled trial", Ann Intern Med, 135, pp.423~433 (2001)
- Tonstad S, "Effect of maintenance therapy with varenicline on smoking cessation : a randomized controlled trial", JAMA, 296, pp.64~71 (2006)
- Schnoll RA, "Effectiveness of extended-duration transdermal nicotine therapy : a randomized trial", Ann Intern Med, 152, pp.144~151 (2010)
- Schnoll RA, "Long-term nicotine replacement therapy : a randomized clinical trial", JAMA Intern Med, 175, pp.504~511 (2015)
- Schlam TR, "Comparative effectiveness of intervention components for producing long-term abstinence from smoking : a factorial screening experiment", Addiction, 111, pp.142~155 (2016)
- "Extended varenicline treatment for smoking among cancer patients" (2012)[URL]
- Bolin K, "Smoking-cessation therapy using varenicline : the cost-utility of an additional 12-week course of varenicline for the maintenance of smoking abstinence", J Eval Clin Pract, 15, pp.478~485 (2009)
- Knight C, "The cost-effectiveness of an extended course(12+12 weeks)of varenicline plus brief counselling compared with other reimbursed smoking cessation interventions in Belgium, from a public payer perspective", Acta Clin Belg, 67, pp.416~422 (2012)
- 2008 PHS Guideline Update Panel, Liaisons, and Staff, "Treating tobacco use and dependence : 2008 update U. S. Public Health Service Clinical Practice Guideline executive summary", Respir Care, 53, pp.1217~1222 (2008)
- West R, "Time for a change : putting the Transtheoretical(Stages of Change)Model to rest", Addiction, 100, pp.1036~1039 (2005)
- Etter JF, "Nicotine replacement to reduce cigarette consumption in smokers who are unwilling to quit : a randomized trial", J Clin Psychopharmacol, 22, pp.487~495 (2002)
- Ebbert JO, "Effect of varenicline on smoking cessation through smoking reduction : a randomized clinical trial", JAMA, 313, pp.687~694 (2015)
- Hughes JR, "Efficacy of varenicline to prompt quit attempts in smokers not currently trying to quit : a randomized placebo-controlled trial", Nicotine Tob Res, 13, pp.955~964 (2011)
- Rennard S, "A randomized placebo-controlled trial of varenicline for smoking cessation allowing flexible quit dates", Nicotine Tob Res, 14, pp.343~350 (2012)
- Evins AE, "Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with psychotic, anxiety, and mood disorders in the EAGLES trial", J Clin Psychopharmacol, 39, pp.108~116 (2019)
- Evins AE, "Efficacy and safety of pharmacotherapeutic smoking cessation aids in schizophrenia spectrum disorders : subgroup analysis of EAGLES", Psychiatr Serv, 72, pp.7~15 (2021)
- Ayers CR, "Efficacy and safety of pharmacotherapies for smoking cessation in anxiety disorders : subgroup analysis of the randomized, active-and placebo-controlled EAGLES trial", Depress Anxiety, 37, pp.247~260 (2020)
- Cinciripini PM, "The effects of varenicline, bupropion, nicotine patch, and placebo on smoking cessation among smokers with major depression : a randomized clinical trial", Depress Anxiety, 39, pp.429~440 (2022)
- Tonnesen P, "Smoking cessation and COPD", Eur Respir Rev, 22, pp.37~43 (2013)
- Antoniu SA, "Pharmacological strategies for smoking cessation in patients with chronic obstructive pulmonary disease : a pragmatic review", Expert Opin Pharmacother, 22, pp.835~847 (2021)
- Le Mao R, "Effect of early initiation of varenicline on smoking cessation in COPD patients admitted for exacerbation : the save randomized clinical trial", COPD, 17, pp.7~14 (2020)
- Tashkin D, "Smoking cessation in patients with chronic obstructive pulmonary disease : a double-blind, placebo-controlled, randomized trial", Lancet, 357, pp.1571~1575 (2001)
- Tashkin DP, "Effects of varenicline on smoking cessation in patients with mild to moderate COPD : a randomized controlled trial", Chest, 139, pp.591~599 (2011)
- Tønnesen P, "Nurse-conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support", Chest, 130, pp.334~342 (2006)
- Wagena EJ, "Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease", Arch Intern Med, 165, pp.2286~2292 (2005)